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Background. Repeat tuberculin skin tests may be false positive due to boosting of waned immunity to past mycobacterial
exposure. We evaluated whether an ELISPOT test could identify tuberculosis (TB) contacts with boosting of immunity to non-
tuberculous mycobacterial exposure. Methodology/Principal Findings. We conducted tuberculin and ELISPOT tests in 1665
TB contacts: 799 were tuberculin test negative and were offered a repeat test after three months. Those with tuberculin test
conversion had an ELISPOT, chest X-ray and sputum analysis if appropriate. We compared converters with non-converters,
assessed the probability of each of four combinations of ELISPOT results over the two time points and estimated boosting with
adjustment for ELISPOT sensitivity and specificity. 704 (72%) contacts had a repeat tuberculin test; 176 (25%) had test
conversion, which increased with exposure to a case (p=0.002), increasing age (p=0.0006) and BCG scar (p=0.06). 114
tuberculin test converters had ELISPOT results: 16(14%) were recruitment positive/follow-up positive, 9 (8%) positive/negative,
34 (30%) negative/positive, and 55 (48%) were negative/negative. There was a significant non-linear effect of age for ELISPOT
results in skin test converters (p=0.038). Estimates of boosting ranged from 32%–41% of skin test converters with increasing
age. Three converters were diagnosed with TB, two had ELISPOT results: both were positive, including one at recruitment.
Conclusions/Significance. We estimate that approximately one third of tuberculin skin test conversion in Gambian TB case
contacts is due to boosting of immunity to non-tuberculous mycobacterial exposure. Further longitudinal studies are required
to confirm whether ELISPOT can reliably identify case contacts with tuberculin test conversion that would benefit most from
prophylactic treatment.
Citation: Hill PC, Jeffries DJ, Brookes RH, Fox A, Jackson-Sillah D, et al (2007) Using ELISPOT to Expose False Positive Skin Test Conversion in
Tuberculosis Contacts. PLoS ONE 2(1): e183. doi:10.1371/journal.pone.0000183
INTRODUCTION
The period of highest risk for developing tuberculosis (TB) is in the
first year after exposure to Mycobacterium tuberculosis.[1] Individuals
most likely to be in this group are those who have a negative test
for M. tuberculosis infection, exposure to a TB case and subsequent
test conversion. However, conversion of the traditional tuberculin
skin test can be confounded by the ‘booster’ phenomenon, whereby
an initial tuberculin injection causes recall of waned cell-mediated
immunity to previous, largely non-tuberculous, mycobacterial
exposure. Tuberculin probably does not cause a truly ‘mycobac-
terially naı ¨ve’ person to become positive on a subsequent test.[2]
Recently, the British National Institute for Health and Clinical
Excellence (NICE) published recommendations suggesting that
the traditional tuberculin test and an interferon-gamma test be
used in a two-step manner – the tuberculin test as a screening tool
and an interferon-gamma test as confirmation.[3] Such a strategy
has not been assessed in practice. It is our view that such a two-
step approach may be most appropriate when trying to distinguish
true tuberculin skin test conversion from that due to the booster
phenomenon, at least in relation to previous non-tuberculous
exposure. One would expect such a phenomenon to occur most
frequently where there is a high rate of BCG vaccination at birth
and intense exposure to environmental mycobacteria, as these are
particularly associated with early skin test reversion [4,5]. The
Gambia is such a setting.
T cell based interferon-gamma assays that incorporate stimu-
latory antigens that are not found in BCG or many environmental
mycobacteria, have been shown to have promise in the diagnosis
of M. tuberculosis infection after recent exposure.[6,7,8] Here we
assess whether ELISPOT has utility in distinguishing tuberculin
skin test converters with true M. tuberculosis infection from those
with boosting of immunity to prior, non-tuberculous, mycobacte-
rial exposure.
METHODS
Participants
Consecutive recruitment of sputum smear and culture positive TB
cases and their household contacts in The Gambia, plus the
selection process for ELISPOT testing, have been described
previously.[7] Household contacts of TB cases were eligible for
inclusion in this study if they were at least 6 months old and had
a recruitment ELISPOT result but were not diagnosed with TB
disease. The study was approved by the combined Gambia
Government/MRC ethics committee.
Contacts were interviewed, examined, and a blood sample
taken for ELISPOT and HIV test. Immediately after the blood
sample was taken they underwent a tuberculin skin test (2 TU,
PPD RT23, Statens Serum Institut, Copenhagen, Denmark).
Those who were tuberculin test negative at recruitment (,10 mm
of induration) were asked to have a repeat tuberculin test at
3 months. Tuberculin test conversion was defined as a positive
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least 6 mm. All tuberculin test converters were asked to have
a chest x-ray and a clinical examination. Those able to produce
sputum underwent sputum analysis. Those diagnosed with TB
disease were referred to the National Programme for free treat-
ment. HIV positive individuals were referred to the MRC HIV
clinic, where they are followed and considered for free anti-
retroviral treatment. There is no current practice of preventive
treatment in The Gambia.
All tuberculin test converters were asked to have a repeat
ELISPOT test. To assess the effect of the tuberculin skin test on
ELISPOT conversion we recruited 32 adult male volunteers from
the general community in The Gambia for tuberculin test and
ELISPOT test. Those that had a negative tuberculin test and
negative ELISPOT test were asked to have a repeat ELISPOT test
after 1 week and 1 month.
Laboratory procedures
Sputum smears were prepared, stained and cultured,[9] plus
HIV tests performed[10] as previously described. We performed
ELISPOT assays in duplicate.[11] Synthetic, sequential peptides
spanning the length of ESAT-6 and CFP-10 (ABC, Imperial
College, London, UK) were used. Each peptide was 15 amino
acids long and overlapped its adjacent peptide by 10 residues. The
ESAT-6 CFP-10 peptide pools were used at a final concentration
of 2.5 mg/ml for each peptide. The positive control was Phytohae-
maglutinin (PHA; Sigma-Aldrich, UK). The ex-vivo ELISPOT
assays were enumerated using an ELISPOT reader (AID-GmbH,
Strasburg, Germany). Positive test wells were pre-defined as con-
taining at least eight spot forming units (SFU) more than negative
control wells.[12] For a positive result it was necessary for at least
one of the pools of overlapping peptides to be positive. PHA wells
were set to at least 150 SFU/well/2610
5 above negative control
wells. Negative control wells were required to have less than 20
SFU/well/2610
5. ELISPOT conversion and reversion was
defined as a positive test or negative test respectively, plus a change
in the combined ESAT-6 and CFP-10 count (above the negative
control) of at least 6 SFU/well/2610
5 (30 SFU/million cells).
Laboratory staff were blinded as to the characteristics of the
individuals tested.
For molecular sub typing of index and secondary case isolates,
we extracted mycobacterial DNA using CTAB and chloroform, as
previously described,[13] and assessed its concentration and purity
by spectrophotometry. We performed Spoligotyping using mem-
branes (Isogen Biosciences), as previously described,[14] scanned
the results and analysed them with software designed in Matlab.
Data management and analysis
The number of SFU in each well were automatically imported into
an Access database using visual basic code and other data were
double-entered into the same database and verified.[15] We
assessed the relationship between conversion and reversion of
tuberculin skin test results to possible risk factors using random
effects logistic regression, taking into account household clustering.
We included age and gender in the final multi-variable model
a priori. For skin test converters with ELISPOT results, the 4
possible combinations of positive or negative baseline and 3-month
follow-up ELISPOT results were fitted using multi-nomial logistic
regression. This is an extension of logistic regression that is used
where there are more than two possible outcomes. After fitting the
predictor effects of sleeping proximity, age and BCG scar status,
the best fit was determined and the predicted probabilities for each
ELISPOT combination were calculated. We then estimated the
proportion of skin test converters with boosting of prior non-
tuberculous mycobacterial exposure, taking into account published
estimates of the sensitivity and specificity of the ELISPOT.[12,16]
Statistical analyses were conducted using Stata software (version 9;
Stata Corp, College Station, TX, USA).
RESULTS
Between May 2002 and September 2004, 2345 contacts of 311 TB
cases were recruited. Of these, 1644 (70%) were selected for an
ELISPOT test in addition to a tuberculin test and had acceptable
results for both (Figure 1). Of these, 799 (48.6%) were tuberculin
test negative and ELISPOT negative and 174 (10.6%) were
tuberculin test negative and ELISPOT positive. Table 1 shows the
characteristics of these contacts and the 704 (72%) who agreed to
have a repeat skin test 3 months later (table 1). Those who were
tested after 3 months were slightly younger than those not tested
again (mean age 17.7 years versus 22.5 years, p,0.0001) and had
a slightly different ethnic mix (p=0.038). Ninety individuals had
an independent second tuberculin reading for quality control:
there was agreement with respect to a positive or negative result in
88 (98%).
One hundred and seventy six (25%) initially negative contacts
had tuberculin test conversion. The proportion of contacts under-
going skin test conversion increased with increasing exposure to
a respective index case according to sleeping proximity (table 2,
p=0.002). It was also increased with increasing age (p=0.0006),
especially up until the age of 30 years, and in those with a visible
BCG scar, although this was of borderline significance (p=0.06).
Those who were ELISPOT positive at initial screening were much
more likely than those who were initially ELISPOT negative to
undergo tuberculin test conversion (p=0.0002).
One hundred and twenty-five (71%) contacts with tuberculin
test conversion agreed to be re-bled for ELISPOT; 114 (91%) had
an acceptable result. While 65% (n=438 of 671; 95% confidence
interval: 61.5%–68.9%) of initially tuberculin test positive contacts
were ELISPOT positive, only 44% (n=50 of 114; 95% confidence
interval: 34.5%–53.5%) of tuberculin test converters were ELI-
SPOT positive. The proportion of tuberculin test converters that
were ELISPOT positive was 34.0% (18 of 53) in those with
a ,15 mm increase induration and 52.5% (32 of 61) of those with
at least 15 mm of induration (p=0.08). Of the 34 tuberculin test
converters who were initially ELISPOT negative and had a
positive repeat ELISPOT at 3 months, 32 (94%) fulfilled criteria
for ELISPOT conversion. Of the 25 initially tuberculin negative,
but ELISPOT positive, individuals that had tuberculin test
conversion, 9 (36%) became ELISPOT negative; all 9 fulfilled
criteria for ELISPOT reversion with a decrease in the combined
ESAT-6/CFP-10 ELISPOT count of at least 6 spots/well.
Using multi-nomial logistic regression we modelled the probab-
ilities of the four possible combinations of recruitment and follow-
up ELISPOT results. There was a significant non-linear effect
for age (p=0.038), but sleeping proximity (p=0.11) and BCG
scar (p-value=0.14) were not significant. Figure 2 represents the
predicted probabilities for each ELISPOT combination according
to age between 5 and 50 years (outside this age range the predicted
probabilities had a 95% confidence interval greater than +/20.1).
Using this figure, the proportion of tuberculin test conversion due
to boosting can be estimated from the predicted probability of
being ELISPOT negative at both recruitment and follow-up:
allowing for a specificity adjustment (assuming 80% specificity of
the ELISPOT), the proportion of skin test converters estimated to
have boosting ranged from 32% to 41% with increasing age.
Of the 32 community volunteers, 14 had a negative tuberculin
test and ELISPOT test. All 14 had a negative ELISPOT test again
ELISPOT to Identify Tuberculin
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all had a negative ELISPOT test.
One hundred and forty (79.5%) skin test converters had an x-
ray performed. Of these, 4 had an x-ray that was suspicious for TB
and were actively investigated. Three cases were identified (table 3).
They ranged from 2 to 10 years of age; all 3 were HIV negative.
With respect to the one that was culture positive, the spoligotype
patterns of the index and secondary case isolates were an exact
match. Both of the cases with ELISPOT results at the two time
points had a rise in their ELISPOT count. One had a strongly
positive ELISPOT at recruitment together with 5 mm of
tuberculin test induration.
DISCUSSION
The interval between initial exposure and tuberculin test conver-
sion has been shown to be a maximum of 6 weeks in 99% of
individuals after BCG vaccination,[17] and 3–7 weeks following
known M. tuberculosis exposure.[18] Furthermore, in The Gambia,
TB cases that commence treatment tend not to be removed from
their family compounds and remain infectious for a period of time
after starting their medication. For these two reasons, a repeat
screening procedure is indicated in Gambian TB case contacts
that are initially negative. Here we present evidence that tuber-
culin skin test conversion after 3 months in such individuals is
relatively increased in certain subgroups, consistent with the
presence of boosting. Second, we have shown that ELISPOT is
not subject to boosting by the tuberculin skin test in community
volunteers. Third we demonstrate that the ELISPOT behaves in
the way one would expect if it were able to distinguish those with
true conversion from those with boosting.
While tuberculin test conversion in this study was associated
with closer proximity to a known TB case, suggesting some genuine
conversion, increased conversion with increasing age and in those
with a BCG scar, provide indirect and direct evidence respectively
of boosting of immunity to previous, largely non-tuberculous,
mycobacterial exposure. Indeed, others have shown that individ-
uals positive on an initial tuberculin test are much more likely to
progress to TB disease than those positive only on a second
test.[19,20]
We found that individuals who were tuberculin skin test
negative and ELISPOT positive at screening were more likely to
undergo tuberculin test conversion. Whether this reflects a shorter
incubation period for the ELISPOT test, or something else,
requires further study. It will also be important to determine
whether ELISPOT converters are more or less likely to be initially
tuberculin test positive at recruitment and if ELISPOT conversion
occurs in the absence of skin test conversion. That 9 (36%) of 25
tuberculin converters who were initially ELISPOT positive had
ELISPOT reversion is of concern. ELISPOT reversion is not
unexpected in theory: the ELISPOT assay detects recently
activated lymphocytes with immediate effector function and
effector-memory cells that persist for a limited time in circulation
once antigen is cleared.[21,22] If M. tuberculosis is either cleared
Figure 1. Study profile.
doi:10.1371/journal.pone.0000183.g001
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antigens may not be consistently secreted, one would expect
ELISPOT test reversion to occur. However, it is likely that some
individuals simply do not mount a strong T cell response to ESAT-
6 or CFP-10 and the T cell response may vary with evolution of an
Table 2. Evaluation of possible factors associated with tuberculin test conversion at 3 months in 704 TB case contacts.
..................................................................................................................................................
3 months conversion
% (n) OR (95% CI) p value Adj OR (95% CI) p value
Sleep proximity Different house 21.8 (56) 1.0 1.0
Different room 22.5 (76) 1.3 (0.8–2.1) 1.2(0.7–2.0)
Same room 40.4 (44) 3.1 (1.7–5.8) 0.0006 2.9 (1.5–5.3) 0.002
Age (years) 0.5–5 16.7 (23) 1.0 1.0
6–15 21.1 (58) 1.6 (0.9–2.9) 1.3 (0.8–2.2)
16–30 34.8 (65) 3.4 (1.8–6.5) 3.2 (1.7–6.2)
.30 28.9 (30) 2.4 (1.2–4.9) 0.0005 1.8 (1.0–3.5) 0.0006
Gender Female 26.6 (101) 1.0
Male 23.2 (75) 0.8 (0.6–1.2) 0.29
Ethnic Group Mandinka 21.9 (59) 1.0
Jola 35.0 (56) 2.0 (1.1–3.6)
Wolof 20.2 (20) 0.7 (0.4–1.6)
Fula 23.4 (11) 1.1 (0.5–2.7)
Other 23.3 (30) 1.0 (0.5–1.9) 0.06
Recruitment ELISPOT negative 21.7 (128) 1.0 1.0
positive 42.5 (48) 3.1 (1.9–5.1) ,0.0001 2.7 (1.6–4.5) 0.0002
BCG scar Absent/uncertain 23.4 (97) 1.0 1.0
Present 27.3 (79) 1.3 (0.9–1.9) 0.21 1.5 (1.0–2.3) 0.06
doi:10.1371/journal.pone.0000183.t002
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Figure 2. Estimates, according to age, of the probability of TB case
contacts that undergo tuberculin conversion having each of the 4
possible combinations of ELISPOT results over the 2 sampling points
(recruitment and after 3 months). The estimates are derived from the
study data using multi-nomial logistic regression and the analysis is
restricted to those aged 5–50 years (see methods). The dotted lines
represent the predicted probabilities if the sensitivity (ELISPOT 2ve:+ve
group) and specificity (ELISPOT 2ve:2ve group) of the ELISPOT are
both 80% (see methods).
doi:10.1371/journal.pone.0000183.g002
Table 1. Characteristics of TB case contacts who were
negative by tuberculin test and ELISPOT at recruitment and
those who had a repeat skin test at 3 months.
......................................................................
Characteristic Recruitment (n=973) 3 months (n=704)
Mean (median: range) age
(years)
19.0 (15:0.5–89) 17.7 (13:0.5–89)
0.5–5 164 (16.9%) 138 (19.6%)
6–15 352 (36.2%) 275 (39.6%)
16–30 299 (30.7%) 187 (26.6%)
.30 158 (16.2%) 104 (14.8%)
Male (%) 455 (46.8%) 324 (46.0%)
Ethnic group
Mandinka 352 (36.2%) 269 (38.2%)
Jola 242 (24.9%) 160 (22.7%)
Wolof 138 (14.2%) 99 (14.1%)
Fula 58 (6.0%) 47 (6.7%)
Other 183 (18.8%) 129 (18.3%)
Proximity to case (%)
Same room 163 (16.8%) 109 (15.5%)
Different room 458 (47.1%) 338 (48.0%)
Different house 352 (36.2%) 257 (36.5%)
BCG scar present 406 (41.7%)
a 289 (41.1%)
c
HIV positive 25 (2.6%)
b 19 (2.7%)
d
a135 (13.9%) had uncertain scar status,
b n=960 tested,
c 101 (14.4%) had
uncertain scar status,
d n=693 tested.
doi:10.1371/journal.pone.0000183.t001
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PLoS ONE | www.plosone.org 4 January 2007 | Issue 1 | e183infection.[23] There is an urgent need for studies of repeated
ELISPOT tests in a large number of TB case contacts. Therefore
we have established a cohort of consecutively recruited TB case
contacts in The Gambia that have a repeat ELISPOT test after 3
and 18 months, and a repeat skin test after 18 months.
Our ELISPOT results suggest that approximately one third
of tuberculin conversion in Gambian TB case contacts is due
boosting of immunity to non-tuberculous mycobacterial exposure.
It is important that a test which can identify individuals who
have boosting can also identify as many as possible of those who
undergo true conversion. Both secondary cases with repeat
ELISPOT results were strongly ELISPOT positive at diagnosis,
and the ELISPOT test probably has sensitivity of 70–85% for
the diagnosis of M. tuberculosis infection from recent exposure in
The Gambia,[12] and 80–90% for the diagnosis of tuberculosis
disease.[16] Sensitivity to disease may vary between certain groups.
For example, the commercial ‘T-spot’ ELISPOT assay detected
only 9 (69%) of 13 cases with pulmonary TB but all 11 cases of
extra-pulmonary TB in a recent study from Italy.[8]
The definition of tuberculin test conversion has been the subject
of considerable debate. We chose a cut-off used previously in The
Gambia,[15,24] in addition to a criterion of at least a 6 mm
increase in induration between tests. This criterion is recom-
mended on the basis that chance variation in the tuberculin test
reading results in less than 6 mm of induration in over 95% of
individuals.[25,26] Using an alternative 10 mm increase in
induration, only 3 fewer contacts would have been included as
skin test converters and the findings of the study were not
significantly altered (data not shown). In The Gambia we have
applied mathematical tools to ELISPOT results in TB cases and
their household contacts to identify a cut-off of 8 spots/well (40
spots/million cells) above the negative control well when using two
antigens.[12] While we cannot be sure that we have identified
exactly the right criterion for ELISPOT conversion, only 2 more
individuals would have been categorised as ELISPOT converters if
no criterion for an increase in spot count had been set, other than
for the test to turn positive; and only 2 individuals would have
been re-categorised as non-converters if a 10 spot increase had
been specified.
At the present time, treatment of M. tuberculosis infection is pro-
hibitively expensive and impractical in many developing countries.
In the United States, it is advised that those case contacts who are
initially screened during the ‘window period’, and have a negative
result, should have a repeat tuberculin test - all those that become
tuberculin positive are offered prophylactic treatment.[27] Any
possible way to help distinguish TB case contacts that would
benefit from prophylactic treatment and those that wouldn’t is
therefore of relevance in both developing and developed country
settings. Further longitudinal studies are indicated to help confirm
that our findings are of practical importance in this regard, and to
address the relevance of ELISPOT reversion in particular. It does
appear that an ELISPOT assay may have a niche in exposing
boosting of immunity to non-tuberculous mycobacterial exposure.
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